Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer

Background: Immune checkpoint inhibitor (ICI) therapy has significantly improved outcomes across a range of malignancies. While infections are a well-known contributor to morbidity and mortality amongst patients receiving systemic chemotherapy regimens, little is known about the impact of infections...

Full description

Bibliographic Details
Main Authors: Ethan A. Burns, Kelly Gee, Ryan B. Kieser, Jiaqiong Xu, Yuqi Zhang, Aubrey Crenshaw, Ibrahim N. Muhsen, Charisma Mylavarapu, Abdullah Esmail, Shivan Shah, Godsfavour Umoru, Kai Sun, Carlo Guerrero, Zimu Gong, Kirk Heyne, Monisha Singh, Jun Zhang, Eric H. Bernicker, Maen Abdelrahim
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
infection
pembrolizumab
non-small cell lung cancer
rate
outcomes
Online Access:https://www.mdpi.com/2072-6694/15/1/81

Internet

https://www.mdpi.com/2072-6694/15/1/81

Similar Items